# A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers

> **NCT01267071** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** A
- **DRUG:** B

## Key facts

- **NCT ID:** NCT01267071
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-14
- **Primary completion:** 2010-09-01
- **Final completion:** 2010-09-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01267071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01267071, "A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01267071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*